Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma China Annual Forum 2017

March 23, 2017 | China, Events, Patient journey, Pei Li Teh, Pharma China Annual Forum, emerging markets 

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00. 

The patient is an important stakeholder in the treatment of chronic conditions in urban China. Patients, as well as their family members, play an important role in determining their own treatment. They decide when to present, they choose the hospital, many pay out of their own pocket for treatments and they are perhaps the key determinant in the duration of therapy. Therefore it is essential  to understand how the patient journey is evolving and the extent to which this will impact the pharmaceutical industry in the next 5 years. 

This paper will outline the universal truths of the chronic disease patient journey in China, as well as the key inflection points that have the biggest impact on treatment outcomes. Finally, by exploring the distinct healthcare challenges that China looks set to face, Pei Li will discuss the potential for pharma to address these challenges using a series of detailed case studies. 

Throughout the event Pei Li will be on hand to answer any questions you might have regarding our expertise and experience in emerging markets. If you are planning to attend the Pharma China Annual Forum and would like to meet with Pei Li, or are unable to attend but would be interested in receiving a copy of the paper please feel free to contact us.

Research Partnership is committed to staying at the cutting edge of healthcare research in emerging markets. As well as attending relevant conferences and exhibitions we are also regular speakers at relevant forums.

Find out more: http://bit.ly/2mXl6PY

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Infographic: Therapy Watch Lupus

Download our latest infographic, which offers an introduction to the real-world patient insights collected by our Therapy Watch Lupus study.

Article: Getting their lives back: Improving options for people with Lupus

Head of Therapy Watch, Helen Parfitt and Head of Living With, Mariel Metcalfe, investigate Lupus from the perspective of both healthcare professionals and patients using data from our syndicated products.

MedTech specialist joins Research Partnership

Janet Powers has joined the company as a Director in the MedTech division.

Interactive: Best Behaviour

Download our curated collection of case studies and other useful resources that illustrate how we apply the principles of behavioural science in our research design.

RP Investigates – Q&A session: Living with Lupus

In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.

Webcast: Demand Assessment

Find out how a study design which better reflects real-world choices can produce a more realistic model for the future market.

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Report: Mexico’s drug market access landscape shake-up: What does it mean for pharma?

Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.